Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
Vera Therapeutics (Nasdaq: VERA) said the FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for progression. In ORIGIN 3 interim analysis, TRUTAKNA cut UPCR 46% vs baseline and 42% vs placebo (statistically significant). Safety in 428 patients included infections (32% vs 28%) and injection reactions (30% vs 5%); long-term kidney benefit pending Q3 2026.
How this was made
The 30-second read
Why it matters
The FDA’s accelerated approval based on a prespecified interim proteinuria endpoint meaningfully improves the probability of commercial viability, while leaving long-term efficacy risk until confirmatory kidney-function benefit is verified.
Market read
Traders can reassess VERA’s risk/reward on a regulatory milestone, but should monitor the accelerated-approval caveat and the upcoming confirmatory endpoint timeline.
What to watch
Key near-term catalysts are the confirmatory ORIGIN 3 eGFR readout anticipated in Q3 2026 and any label/uptake details not covered here; safety signals (infections/local reactions) could also affect uptake assumptions.
Background
TRUTAKNA (atacicept-vymj) is a BAFF and APRIL inhibitor targeting immunological drivers of IgA nephropathy; ORIGIN 3 is an ongoing Phase 3 program.
Ticker impact
Vera Therapeutics received FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy.
Likely near-term positive repricing on approval headline; subsequent volatility tied to ORIGIN 3 confirmatory readout expectations and any safety/labeling details.
The article discloses a first-in-class BAFF/APRIL inhibitor approval, interim ORIGIN 3 proteinuria results, and explicitly notes accelerated approval contingency on later eGFR benefit verification.
Market effects
Strengthens the BAFF/APRIL pathway validation in IgA nephropathy and may raise competitive expectations for other immunology-driven kidney programs.
US regulatory milestone can improve US biotech risk appetite for nephrology/immune-mediated disease names.
IgA nephropathy is a global CKD driver; approval may influence international payer/launch planning and future trial designs worldwide.
Counterpoint
Because this is accelerated approval based on proteinuria (not yet kidney-function decline), the market may fade gains if investors discount the durability of benefit until ORIGIN 3 eGFR results.
Key entities
- companyVera Therapeutics, Inc.
Nasdaq-listed biotech that announced FDA accelerated approval for TRUTAKNA in primary IgA nephropathy.
- drugTRUTAKNA (atacicept-vymj)
BAFF and APRIL inhibitor administered as a 150 mg once-weekly subcutaneous autoinjector.
- clinical_trialORIGIN 3 trial
Ongoing randomized, double-blind, placebo-controlled Phase 3 trial; interim analysis drove accelerated approval.
- regulatorU.S. Food and Drug Administration (FDA)
Granted accelerated approval contingent on confirmatory clinical benefit verification.
